Reclast (Zoledronic Acid) FAERS Safety Signals

FDA Approval History and Regulatory Timeline

The FDA approved zoledronic acid 5 mg (Reclast) on August 20, 2007, for treatment of postmenopausal osteoporosis, based on the HORIZON-PFT trial that enrolled 7,765 women across 27 countries [1]. A second approval for osteoporosis prevention at a once-every-two-years schedule followed in 2009 [2].

Prior to Reclast, zoledronic acid had been marketed since 2001 as Zometa (4 mg IV monthly) for oncologic indications including hypercalcemia of malignancy and bone metastases [3]. This dual-indication history is important for interpreting FAERS data because adverse event reports filed against "zoledronic acid" often conflate oncology and osteoporosis dosing regimens. A 2014 pharmacovigilance analysis in Drug Safety found that approximately 40% of FAERS reports listing zoledronic acid did not specify the indication, complicating signal detection [4].

The FDA has issued multiple label revisions since approval. The 2010 update added class-wide bisphosphonate warnings for atypical femoral fractures. A 2011 revision strengthened renal impairment warnings after post-market reports of acute kidney injury. The current prescribing information runs to 27 pages and includes five boxed-adjacent warnings [2].

FAERS Overview: How Safety Signals Are Detected

FAERS (the FDA Adverse Event Reporting System) is the primary post-market surveillance database used by the FDA's Office of Surveillance and Epidemiology to monitor drug safety after approval [5]. Reports come from manufacturers (mandatory), healthcare providers, and patients (voluntary). The database contains over 29 million reports as of early 2026.

Signal detection uses disproportionality analysis. The most common metric is the reporting odds ratio (ROR), which compares the observed frequency of a drug-event combination against the expected frequency across all drugs in the database. An ROR above 2.0 with a lower 95% confidence interval above 1.0 typically triggers a formal safety review [5]. For zoledronic acid, multiple signals have crossed this threshold, and several have resulted in regulatory action.

A signal in FAERS does not prove causation. Reporting biases, including notoriety bias (clinicians report events they have read about) and Weber effect (reports spike in the first two years after approval), can inflate signal strength. The FDA uses FAERS signals as hypothesis generators, then evaluates them against controlled trial data, Sentinel System analyses, and published epidemiologic studies before acting [6].

Atrial Fibrillation: The First Major Post-Approval Signal

The atrial fibrillation (AF) signal emerged before Reclast even accumulated substantial FAERS data. In the HORIZON-PFT trial itself, serious atrial fibrillation events occurred in 50 of 3,862 zoledronic acid patients (1.3%) compared with 20 of 3,852 placebo patients (0.5%), yielding a P-value of 0.006 [1]. This finding was unexpected and prompted immediate regulatory scrutiny.

The FDA convened an advisory committee review in 2008 that examined FAERS reports, HORIZON-PFT data, and data from the HORIZON-RFT recurrent fracture trial [7]. The advisory committee concluded that no consistent AF signal existed across trials. The HORIZON-RFT trial showed no significant difference in AF rates (1.1% vs. 1.3% placebo) [8]. A meta-analysis by Sharma et al. published in Chest (2013) pooled data from 22 randomized trials of bisphosphonates (N=37,302) and found no statistically significant increase in AF risk (RR 1.07, 95% CI 0.96 to 1.20) [9].

The current Reclast label lists atrial fibrillation under "Adverse Reactions" based on HORIZON-PFT data but does not include a specific warning or precaution [2]. The Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacotherapy states: "The atrial fibrillation signal observed in HORIZON-PFT has not been replicated in subsequent trials or large observational studies, and should not preclude use of zoledronic acid in appropriate patients" [10].

Osteonecrosis of the Jaw (ONJ)

ONJ is the most publicly recognized safety signal for all bisphosphonates, and FAERS data reflect that visibility. The pathologic definition requires exposed bone in the maxillofacial region persisting for more than 8 weeks in a patient with bisphosphonate exposure and no history of radiation therapy to the jaw [11].

The risk is heavily dose-dependent. A 2015 systematic review by Khan et al. published in the Journal of Bone and Mineral Research, which informed the American Dental Association's position, estimated ONJ incidence at 0.001% to 0.01% per year among osteoporosis patients receiving oral or annual IV bisphosphonates, compared with 1% to 15% per year in cancer patients receiving monthly IV zoledronic acid (Zometa) at 4 mg doses [11]. That represents a roughly 1,000-fold difference in risk between indications.

FAERS data on ONJ for zoledronic acid are heavily confounded by this dosing distinction. A 2012 analysis by the FDA's Sentinel System reviewed insurance claims for 218,000 bisphosphonate users and found only 9 confirmed ONJ cases among non-cancer patients receiving any bisphosphonate, corresponding to an incidence of approximately 0.004% [12].

The Reclast label carries a "Warnings and Precautions" section on ONJ that recommends dental examination before initiating therapy in patients with risk factors such as cancer, chemotherapy, corticosteroid use, poor oral hygiene, or planned invasive dental procedures [2]. The American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper recommends against routine drug holidays before dental extractions for osteoporosis-dose bisphosphonates, stating: "The risk of ONJ at osteoporosis treatment doses is exceedingly low, and the benefit of continued fracture protection outweighs the marginal ONJ risk reduction from drug discontinuation" [13].

Atypical Femoral Fractures (AFFs)

AFFs are subtrochanteric or diaphyseal femur fractures with specific radiographic features (transverse fracture line, lateral cortical beaking, minimal comminution) that occur with low-energy trauma [14]. The FDA added a class-wide warning for AFFs to all bisphosphonate labels in October 2010 after FAERS signal detection and case series publications [15].

The absolute risk is small but increases with duration of use. The landmark study by Dell et al. (2012) using Kaiser Permanente data (N=1.8 million person-years of bisphosphonate exposure) found AFF incidence rose from 1.78 per 100,000 person-years in the first two years of use to 113.1 per 100,000 person-years after 8 or more years [16]. This duration-dependent signal is the primary evidence base for the concept of "bisphosphonate holidays," now endorsed by the American Society for Bone and Mineral Research (ASBMR) for patients at lower fracture risk after 3 to 5 years of therapy [14].

For zoledronic acid specifically, the HORIZON-PFT extension study followed patients for 6 years total (3 years of active treatment plus 3 years of extension) and reported zero confirmed AFFs in either the continued-treatment or placebo-switch groups [17]. The low event rate at typical osteoporosis treatment durations (3 annual infusions) provides some reassurance, but the FDA label warning applies regardless of bisphosphonate type or route [2].

Patients should be instructed to report new thigh or groin pain, which may represent a prodromal stress reaction. Plain radiography of both femurs is the first-line imaging study if AFF is suspected [14].

Renal Toxicity

Acute kidney injury (AKI) is the safety signal that has generated the most direct regulatory action for Reclast. Zoledronic acid is cleared renally, and the 5 mg dose infused over 15 minutes delivers a substantial bisphosphonate load to the kidneys in a single session [2].

In HORIZON-PFT, transient serum creatinine elevations (increases >0.5 mg/dL) occurred in 1.2% of zoledronic acid patients versus 0.4% of placebo patients within 9 to 11 days post-infusion [1]. Most elevations resolved within 30 days. Post-marketing, however, FAERS accumulated cases of acute renal failure, some requiring dialysis. A 2011 FDA Drug Safety Communication noted 24 reports of acute renal failure associated with Reclast, including two fatalities [18].

The FDA responded by strengthening the label in three ways. First, Reclast is now contraindicated in patients with creatinine clearance <35 mL/min [2]. Second, the label mandates measurement of serum creatinine before each annual dose. Third, the recommended infusion time was clarified as "no less than 15 minutes," because faster infusion rates increase peak renal drug concentrations [2].

A 2016 retrospective cohort study using the Sentinel System (N=122,340 zoledronic acid infusions) found AKI within 30 days in 0.24% of patients with normal baseline renal function and 1.8% of patients with baseline CrCl 35 to 60 mL/min [19]. Adequate hydration before infusion (at least 500 mL of normal saline or oral equivalent) is the primary risk mitigation strategy and is recommended on the label.

Acute Phase Reaction

The most common adverse event reported in both clinical trials and FAERS for zoledronic acid is the acute phase reaction (APR), sometimes called the "post-infusion syndrome." Symptoms include fever, myalgia, arthralgia, headache, and fatigue, typically beginning within 24 to 72 hours of infusion and resolving within 3 days [1].

In HORIZON-PFT, APR-related symptoms occurred in 31.6% of patients after the first infusion, dropping to 6.6% after the second annual dose and 2.8% after the third [1]. The reaction is mediated by transient release of pro-inflammatory cytokines (TNF-alpha, IL-6) from peripheral blood gamma-delta T cells activated by bisphosphonate-induced accumulation of isopentenyl pyrophosphate [20].

Pre-treatment with acetaminophen (650 mg to 1,000 mg given 30 to 60 minutes before infusion) reduces APR incidence by approximately 40% based on a randomized controlled trial by Silverman et al. (2007, N=108) [21]. Some clinicians also recommend ibuprofen 400 mg as an alternative. The reaction does not indicate allergy, and patients should be counseled before their first infusion that flu-like symptoms are expected and transient.

Hypocalcemia

Zoledronic acid potently inhibits osteoclastic bone resorption, which can acutely lower serum calcium. The Reclast label requires correction of pre-existing hypocalcemia and vitamin D deficiency before infusion and recommends supplementation with calcium 1,200 mg/day and vitamin D 800 to 1,000 IU/day [2].

In HORIZON-PFT, 0.2% of zoledronic acid patients experienced symptomatic hypocalcemia compared with 0.1% of placebo patients [1]. Post-market FAERS reports have flagged symptomatic hypocalcemia primarily in patients with unrecognized vitamin D deficiency (25-OH-D <20 ng/mL), chronic kidney disease, or malabsorption syndromes [2]. The 2020 AACE/ACE clinical practice guidelines for osteoporosis diagnosis and treatment state: "Vitamin D repletion to at least 30 ng/mL should be confirmed by laboratory testing before administering IV zoledronic acid to prevent clinically significant hypocalcemia" [22].

Sentinel System and Active Surveillance

FAERS relies on passive, voluntary reporting, which captures only an estimated 1% to 10% of actual adverse events (a phenomenon called the "reporting fraction") [5]. The FDA Sentinel System, launched in 2008, addresses this limitation through active surveillance of distributed data from 18 collaborating health plans covering over 100 million patients [6].

Sentinel analyses have been particularly informative for zoledronic acid. The 2016 renal toxicity assessment described above [19] used Sentinel data to quantify absolute incidence rates that FAERS alone cannot generate. A separate Sentinel analysis evaluated ONJ risk across bisphosphonate types and found no statistically significant difference between oral alendronate and IV zoledronic acid at osteoporosis doses (adjusted hazard ratio 0.92, 95% CI 0.41 to 2.06) [12].

The EMA's EudraVigilance database has generated concordant signals for zoledronic acid, with the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) issuing parallel recommendations to the FDA on AFFs (2011), renal monitoring (2012), and ONJ dental screening (2015) [23].

Putting FAERS Signals in Clinical Context

FAERS data can alarm patients who encounter raw report counts without denominator context. Zoledronic acid has accumulated a large absolute number of FAERS reports because it has been on the market since 2001 (as Zometa) and 2007 (as Reclast), with millions of cumulative exposures worldwide [4].

The benefit-risk profile remains favorable for appropriate patients. HORIZON-PFT demonstrated a 70% reduction in vertebral fractures (3.3% vs. 10.9%, P<0.001), a 41% reduction in hip fractures (1.4% vs. 2.5%, P=0.002), and a 25% reduction in non-vertebral fractures (8.0% vs. 10.7%, P<0.001) over 3 years [1]. The HORIZON-RFT trial, enrolling patients with a recent hip fracture, showed a 28% reduction in all clinical fractures and, notably, a 28% reduction in all-cause mortality (9.6% vs. 13.3%, P=0.01) [8].

For patients with osteoporosis who meet prescribing criteria (CrCl ≥35 mL/min, adequate vitamin D levels, no active ONJ risk factors), the number needed to treat to prevent one vertebral fracture over 3 years is approximately 13, while the number needed to harm for the most clinically relevant serious adverse events (AKI requiring hospitalization) is approximately 420 based on Sentinel data [1][19]. Clinicians should review FAERS signals as context for informed consent, not as contraindications in isolation. Pre-infusion creatinine clearance and 25-OH-D measurement remain the two most actionable safety steps before each annual dose [2].